Specifying a Second-Site GMP Drug Substance Technology Transfer for a Licensed Fc-Fusion Biologic: A Request-for-Proposal Framework for Comparability and Process Validation
A biologic approved under an accelerated pathway can be on the market before its confirmatory evidence is complete, so any manufacturing shortfall becomes a patient-access problem, not a delay in a clinical trial. This article builds the rationale and the request for proposal (RFP) for a technology transfer and process validation campaign that would qualify a second site or a scaled bioreactor train for a hypothetical licensed decoy-receptor Fc-fusion protein produced in Chinese hamster ovary cells. The rationale separates demonstrated facts from sponsor assumptions, treats glycosylation as a process-sensitive quality attribute of the product class, and argues that a second qualified source removes a single point of failure. The RFP specifies a 2,000 L campaign with two engineering runs and three GMP validation lots, an orthogonal comparability panel, dependency-based milestones with an 18 to 20 month duration, a budget of USD 8.7 to 12.15 million, a weighted scoring framework, and the confidentiality and intellectual property protections to put in place before issuing the request.Keywords: request for proposal; Fc-fusion protein; technology transfer; comparability; glycosylation; ICH Q5E; process validation; CDMO
Authors
- Peivand Pirouzi
- Perpetua Ulofu
- Uchechukwu Veronica Ikechukwu
- Yemurayi Hungwe
- Precious Chinenye Sunday
Institutions
- Northeastern University (US)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24425345
- Primary Topic
- Viral Infectious Diseases and Gene Expression in Insects
- Type
- article
- Field-Weighted Citation Impact
- 0.00